Vivet Therapeutics - innovative gene therapy treatments for orphan diseases
innovative gene therapy treatments for orphan diseases
Toggle menu
About us
Our DNA
Board members
Our leadership
Partners
Pipeline
VTX-801 – Wilson’s disease
> VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
VTX-802 & VTX-803 – PFIC
VTX-804 – Citrullinemia Type 1
Investors
News
Events
Patients & Families
Patient advocacy
Patient & Families ressources
Compassionate Use and Expanded Access
Work at Vivet
Members
Vivet Therapeutics
→
Members
Roche Venture Fund
Carole Nuechterlein
Ysios Capital
Karen Wagner, PhD
HealthCap
Mårten Steen, MD, PhD
Kurma Partners
Amanda Gett-Chaperot, PhD, MBA
Novartis Venture Fund
Beat Steffen, MD, MBA
Columbus Venture Partners
Javier García, MBA